Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Max Bayer

Pharma Reporter

A Blue Cross Blue Shield licensee serving parts of Pennsylvania says it will not cover some therapies granted accelerated approval for at least 18 months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Max Bayer

Pharma Reporter

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Re­gen­eron buys Lon­don-based oc­u­lar biotech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

No­vo pe­ti­tions FDA over Vic­toza com­pound­ing as first gener­ic wins ap­proval

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Novo petitions FDA over Victoza compounding as first generic wins approval